Study Evaluating Changes In Mammographic Breast Density
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate quantitative changes in mammographic breast density
from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20
mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this
study is the change in mammographic breast density between baseline and month 24 for each
group.